The COVID-19 Pandemic Effect On Advocacy: Perspective From Mental Health America
Mr. Paul Gionfriddo, President and CEO of Mental Health America (MHA), and Dr. Dennis Pabis, Senior Medical Science Liaison with Otsuka Pharmaceutical Development & Commercialization, Inc., discuss the effects of the COVID-19 pandemic on the efforts of advocacy organizations, including MHA. They discuss how MHA is addressing the unique challenges COVID-19 poses to those affected by trauma-related symptoms. They also share their thoughts on legislation regarding telehealth rules, as well as resources that MHA has available for patients and caregivers.
Paul …
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). Specific PsychU programs may be supported by OPDC, OAPI and other committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsor or the sponsors of the specific PsychU program in which such opinions are expressed. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC and OAPI.